The HCFC1R1 Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the TE1 human esophageal squamous cell carcinoma (ESCC) line, featuring targeted disruption of the HCFC1R1 gene. This loss-of-function model enables investigation of HCFC1R1 in a cancer-relevant background. The polyclonal format preserves a heterogeneous mixture of edited alleles, mimicking genetic diversity and allowing phenotypic assessment without clonal selection bias. These ready-to-use cells support applications in functional genomics and cancer cell biology.
The TE1 cell line is a well-characterized model of ESCC, originating from esophageal epithelial cells and exhibiting hallmark dysregulated proliferation and aberrant cell cycle control. It serves as a standard in vitro system for dissecting molecular mechanisms of esophageal carcinogenesis and evaluating therapeutic candidates. The esophageal epithelial context makes TE1 particularly relevant for studying genes involved in cell cycle regulation and tumor suppression.
At the molecular level, HCFC1R1 functions as a direct negative regulator of the transcriptional coactivator HCFC1 (host cell factor C1). HCFC1 collaborates with E2F transcription factors to drive expression of cell cycle drivers such as cyclin D1 and CDK4. HCFC1R1 binds HCFC1 and restricts its coactivator activity, thereby dampening E2F transcriptional output. CRISPR/Cas9-mediated disruption of HCFC1R1 relieves this repression, leading to elevated HCFC1 function and increased expression of downstream cell cycle genes. This mechanism places HCFC1R1 upstream of the E2F/cyclin/CDK axis, potentially acting as a tumor suppressor by restraining G1/S progression. The knockout cells exhibit a de-repressed state that promotes proliferative gene programs.
In ESCC, cell cycle dysregulation is a hallmark of malignancy. This knockout model enables dissection of how loss of HCFC1R1-mediated inhibition of HCFC1 contributes to uncontrolled proliferation. Researchers can probe the consequences on cell cycle progression, E2F target gene induction, and tumorigenic behavior in an esophageal epithelial background. The system is valuable for identifying dependencies on HCFC1-driven transcription in esophageal cancer.
Experimental applications include cell proliferation assays (MTT, BrdU), flow cytometry-based cell cycle analysis, western blotting for HCFC1R1, HCFC1, cyclin D1, CDK4, and E2F targets, and RNA-seq for transcriptome-wide profiling. Co-immunoprecipitation verifies disrupted HCFC1?CHCFC1R1 interaction, while colony formation assays assess long-term proliferative capacity. These approaches elucidate HCFC1-mediated transcription and cell cycle control in ESCC. For further inquiries or custom gene editing services, contact Ascent Research.
